Regeneron Pharmaceuticals

Health Care Biotechnology Tarrytown, New York Last filing Feb 4, 2026 · FY2025

Balance Sheet

Assets, liabilities, and equity

13 accounts · 5 years

Account	2025	2024	2023	2022	2021
Statement
BS Assets Cash	$0	$2.5B	$2.7B	$3.1B	$2.9B
BS Assets Accts Receivable	$0	$6.2B	$5.7B	$5.3B	$6.0B
BS Assets Inventory	$0	$3.1B	$2.6B	$2.4B	$2.0B
BS Assets PPE	$0	$4.6B	$4.1B	$3.8B	$3.5B
BS Assets Intangible Assets	$0	$1.1B	$1.0B	$915.5M	$0
BS Assets Other Noncurrent	$0	$1.1B	$444.1M	$336.4M	$222.8M
BS Liab Accrued Liab	$0	$571.1M	$666.7M	$637.5M	$383.9M
BS Liab Other Current	$0	$213.2M	$0	$0	$326.3M
BS Liab Long Term Debt	$0	$2.0B	$2.0B	$2.0B	$2.0B
BS Liab Other Noncurrent	$0	$1.6B	$854.1M	$638.0M	$680.2M
BS Equity Preferred Stock	$0	$0	$0	$0	$0
BS Equity Common Stock	$0	$0	$0	$0	$0
BS Equity Treasury Stock	$0	$15.2B	$12.6B	$10.4B	$8.3B

Income Statement

Revenue, expense, and profitability

19 accounts · 5 years

Revenue $14.3B

Operating income $3.6B

Net income $4.5B

Account	2025	2024	2023	2022	2021
Statement
IS Revenue Total	$14.3B	$14.2B	$13.1B	$12.2B	$16.1B
IS Expense COGS	$10.8B	$10.2B	$9.1B	$7.4B	$7.1B
IS Expense Rn D	$5.9B	$5.1B	$4.4B	$3.6B	$2.9B
IS Expense SGA	$2.7B	$3.0B	$2.6B	$2.1B	$1.8B
IS Expense DA	$543.7M	$482.9M	$421.0M	$341.4M	$286.2M
IS Expense SBC	$993.7M	$982.8M	$885.0M	$725.0M	$601.7M
IS Expense Total Opex	$10.8B	$10.2B	$9.1B	$7.4B	$7.1B
IS Operating Income	$3.6B	$4.0B	$4.0B	$4.7B	$8.9B
IS Interest Income	$716.8M	$711.4M	$495.9M	$160.1M	$45.8M
IS Interest Expense	$43.8M	$55.2M	$73.0M	$59.4M	$57.3M
IS Other Nonop Inc Exp	$1.7B	$844.4M	$225.2M	$179.3M	$436.3M
IS Pre Tax Income	$5.2B	$4.8B	$4.2B	$4.9B	$9.3B
IS Tax Expense	$725.8M	$367.3M	$245.7M	$520.4M	$1.3B
IS net Income	$4.5B	$4.4B	$4.0B	$4.3B	$8.1B
IS Comprehensive Income	$4.6B	$4.5B	$4.1B	$4.1B	$8.0B
IS EPS Basic	$43	$41	$37	$41	$76
IS EPS Diluted	$41	$38	$35	$38	$72
IS Shares Basic	$104.6M	$107.9M	$106.7M	$107.1M	$105.7M
IS Shares Diluted	$108.6M	$115.1M	$113.7M	$113.5M	$112.2M

Cash Flow Statement

Operating, investing, and financing flows

18 accounts · 5 years

Account	2025	2024	2023	2022	2021
Statement
CF Ops net Income	$4.5B	$4.4B	$4.0B	$4.3B	$8.1B
CF Ops DA	$543.7M	$482.9M	$421.0M	$341.4M	$286.2M
CF Ops SBC	$993.7M	$982.8M	$885.0M	$725.0M	$601.7M
CF Ops Deferred Tax	$-785.4M	$-757.3M	$-837.8M	$-746.4M	$-147.1M
CF Ops Working Capital	$100.8M	$1.8B	$768.5M	$169.7M	$2.5B
CF Ops net Cash	$5.0B	$4.4B	$4.6B	$5.0B	$7.1B
CF Inv Acquisitions	$3.3M	$16.5M	$54.9M	$230.3M	$0
CF Inv Purchase Investments	$11.0B	$16.6B	$11.6B	$7.5B	$7.0B
CF Inv Proceeds Investments	$11.5B	$15.0B	$9.4B	$5.6B	$2.2B
CF Inv net Cash	$-629.1M	$-2.5B	$-3.2B	$-3.8B	$-5.4B
CF Fin Share Repurchases	$3.4B	$2.6B	$2.2B	$2.1B	$1.6B
CF Fin Dividends	$370.3M	$0	$0	—	—
CF Fin Stock Issuance	$635.9M	$1.5B	$1.1B	$1.5B	$1.7B
CF Fin Tax Withholding	$532.1M	$1.0B	$700.6M	$445.7M	$1.0B
CF Fin Other	$-10.3M	$-33.4M	$0	$0	—
CF Fin net Cash	$-3.7B	$-2.2B	$-1.8B	$-1.0B	$-1.0B
CF FX Effect	$300.0K	$-700.0K	$-400.0K	$0	$0
CF net Change	$634.7M	$-248.8M	$-381.6M	$221.3M	$690.8M

Stock Data

One-year price and volume history

Data not loaded

Price data unavailable

Stock price history for REGN has not been loaded yet.

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

One-year price and volume history

Price data unavailable

Recent price history